Cardiovascular Events in Parkinson's Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-09-30

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiovascular (CV) disease is a common comorbidity of Parkinson's disease (PD). The background incidence rate of CV events in a levodopa-treated PD population was assessed to better understand these comorbidities in the PD population. One objective of the study is to identify a population of prevalent PD patients with incident levodopa use within the years 2004-2010 on the Integrated Health Care Information Services (IHCIS) database. The second objective is to report the incidence of CV events overall and during intervals 0-6, 6-12 and 12-18 months after first prescription of levodopa among all new levodopa users.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiac Changes in Early Parkinson's Disease: a Follow Up Study

NCT04218968

REM Sleep Behavior Disorder Pre-motor Parkinson Disease Symptomatic Parkinson Disease

ENROLLING_BY_INVITATION PHASE2

Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease

NCT05487300

Parkinson Disease Orthostatic Hypotension

COMPLETED PHASE2/PHASE3

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

NCT04056689

Parkinson's Disease

COMPLETED PHASE1

Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

NCT00558337

Parkinson's Disease

COMPLETED PHASE2

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

NCT05083260

Parkinson Disease

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Event Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

New levodopa users

Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 but no previous levodopa prescriptions prior to study period

levodopa

Intervention Type DRUG

levodopa use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

levodopa

levodopa use

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010
* Individuals on the database with medical and pharmacy benefit for at least 6 months prior to date of first prescription of levodopa
* Individuals with one or more diagnosis codes for Parkinson's disease within the 6 months prior or 6 months post first prescription of levodopa